Search Results

Abiomed, part of Johnson & Johnson MedTech1, announced that novel data from seven research studies focused on optimizing outcomes for patients receiving Impella-supported high-risk percutaneous coronary intervention (HRPCI) will be presented at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium taking place in San Francisco between Oct. 24 - 26.

Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced it has completed its acquisition of Abiomed, Inc.

Johnson & Johnson announced it was acquiring all outstanding shares of Abiomed for $16.6 billion to expand Abiomed’s cardiovascular technologies and increase patient access.

TELA Bio, Inc. announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson’s MedTech Segment, to its Board of Directors, effective June 4, 2024.

Abiomed, Inc . (NASDAQ: ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023.

Abiomed announces a new program to address healthcare disparities in underserved communities, as new data provides an example of how better access to Impella heart pumps can improve health equity for non-Caucasian cardiovascular patients.

ABIOMED, Inc. today announces financial results for the quarter ended September 30, 2022.

Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, August 4, 2022, the Company will release financial results for the first quarter of the fiscal year 2023.

Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference.

Abiomed (NASDAQ: ABMD) announces the successful results of the first-in-human early feasibility study of the preCARDIA system.